Literature DB >> 30643228

Transcriptomic predictors of inflammation-induced depressed mood.

Joshua Hyong-Jin Cho1, Michael R Irwin2, Naomi I Eisenberger3, Donald M Lamkin2, Steve W Cole2.   

Abstract

Inflammation plays a significant role in the pathophysiology of depression. However, not all individuals exposed to inflammatory challenge develop depression, and identifying those at risk is necessary to develop targeted monitoring, prevention, and treatment strategies. Within a randomized double-blind placebo-controlled study (n = 115), we examined whether leukocyte transcriptome profiles predicted inflammation-induced depressed mood in volunteers who received low-dose intravenous endotoxin (n = 58; aged 18-50). At baseline, transcription factor (TF) activities were assessed using genome-wide transcriptional profiling of peripheral blood mononuclear cells and promoter-based bioinformatic analyses. Then, participants were administered endotoxin. Self-reported depressed mood was assessed using the Profile of Mood States. Based on extant studies linking transcriptional profiles to depressive disorder, we examined whether post-endotoxin depressed mood is predicted by baseline activity of TFs related to immune activation, sympathetic activation, and glucocorticoid insensitivity: respectively, nuclear factor kappa B (NF-kB), cAMP response element-binding protein (CREB), and glucocorticoid receptor (GR). Twenty-one participants (36%) experienced an increase in depressed mood from baseline to 2 h post endotoxin, when depressive response peaks. Bioinformatics analyses controlling for age, sex, ethnicity, body mass index, and physical sickness response revealed that post-endotoxin depressed mood was predicted by increased baseline activity of TFs related to inflammation (NF-kB) and beta-adrenergic signaling (CREB) and by decreased activity of GR-related TFs (P's < 0.001). Inflammation-induced depressed mood is predicted by peripheral transcriptome profiles related to immune activation, sympathetic activation, and glucocorticoid insensitivity. With further replication, these stress-related molecular profiles could be used for a novel genomic approach for identifying individuals at high-risk for the inflammatory subtype of depression.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30643228      PMCID: PMC6462041          DOI: 10.1038/s41386-019-0316-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  52 in total

Review 1.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment.

Authors:  C M Pariante; A H Miller
Journal:  Biol Psychiatry       Date:  2001-03-01       Impact factor: 13.382

2.  Human fibroblasts as a relevant model to study signal transduction in affective disorders.

Authors:  D H Manier; R C Shelton; T C Ellis; C S Peterson; A Eiring; F Sulser
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

3.  A POMS short form for cancer patients: psychometric and structural evaluation.

Authors:  Frank Baker; Maxine Denniston; James Zabora; Adrienne Polland; William N Dudley
Journal:  Psychooncology       Date:  2002 Jul-Aug       Impact factor: 3.894

4.  Expression-based monitoring of transcription factor activity: the TELiS database.

Authors:  Steve W Cole; Weihong Yan; Zoran Galic; Jesusa Arevalo; Jerome A Zack
Journal:  Bioinformatics       Date:  2004-09-16       Impact factor: 6.937

Review 5.  The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression.

Authors:  Fridolin Sulser
Journal:  Ann Med       Date:  2002       Impact factor: 4.709

6.  Cytokine-associated emotional and cognitive disturbances in humans.

Authors:  A Reichenberg; R Yirmiya; A Schuld; T Kraus; M Haack; A Morag; T Pollmächer
Journal:  Arch Gen Psychiatry       Date:  2001-05

7.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

Review 8.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

Authors:  Katsuhiko Ishihara; Toshio Hirano
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

9.  Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.

Authors:  Lucile Capuron; Alain Ravaud; Andrew H Miller; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2004-05       Impact factor: 7.217

10.  Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits.

Authors:  Yogesh Dwivedi; Hooriyah S Rizavi; Pradeep K Shukla; Jennifer Lyons; Gabor Faludi; Miklos Palkovits; Andrea Sarosi; Robert R Conley; Rosalinda C Roberts; Carol A Tamminga; Ghanshyam N Pandey
Journal:  Biol Psychiatry       Date:  2004-02-01       Impact factor: 13.382

View more
  12 in total

1.  Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes.

Authors:  Dhivya Arasappan; Simon B Eickhoff; Charles B Nemeroff; Hans A Hofmann; Mbemba Jabbi
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

2.  Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study.

Authors:  Haidong Lu; Pamela J Surkan; Michael R Irwin; Glenn J Treisman; Elizabeth C Breen; Ned Sacktor; Ron Stall; Steven M Wolinsky; Lisa P Jacobson; Alison G Abraham
Journal:  Am J Epidemiol       Date:  2019-11-01       Impact factor: 4.897

3.  Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study.

Authors:  Jennifer L Kruse; Joshua Hyong-Jin Cho; Richard Olmstead; Lin Hwang; Kym Faull; Naomi I Eisenberger; Michael R Irwin
Journal:  Psychoneuroendocrinology       Date:  2019-07-03       Impact factor: 4.905

4.  Depressive symptoms and other negative psychological states relate to ex vivo inflammatory responses differently for men and women: Cross-sectional and longitudinal evidence.

Authors:  Erik L Knight; Marzieh Majd; Jennifer E Graham-Engeland; Joshua M Smyth; Martin J Sliwinski; Christopher G Engeland
Journal:  Physiol Behav       Date:  2021-11-25

5.  Sex Differences in the Effect of Inflammation on Subjective Social Status: A Randomized Controlled Trial of Endotoxin in Healthy Young Adults.

Authors:  Mona Moieni; Keely A Muscatell; Ivana Jevtic; Elizabeth C Breen; Michael R Irwin; Naomi I Eisenberger
Journal:  Front Psychol       Date:  2019-10-01

6.  Transcriptomic signaling pathways involved in a naturalistic model of inflammation-related depression and its remission.

Authors:  Marie-Pierre Moisan; Aline Foury; Sandra Dexpert; Steve W Cole; Cédric Beau; Damien Forestier; Patrick Ledaguenel; Eric Magne; Lucile Capuron
Journal:  Transl Psychiatry       Date:  2021-04-06       Impact factor: 6.222

7.  Design and protocol of the multimorbidity and mental health cohort study in frailty and aging (MiMiCS-FRAIL): unraveling the clinical and molecular associations between frailty, somatic disease burden and late life depression.

Authors:  Ivan Aprahamian; Ronei Luciano Mamoni; Nilva Karla Cervigne; Taize Machado Augusto; Carla Vasconcelos Romanini; Marina Petrella; Daniele Lima da Costa; Natalia Almeida Lima; Marcus K Borges; Richard C Oude Voshaar
Journal:  BMC Psychiatry       Date:  2020-12-01       Impact factor: 3.630

8.  Moderators of inflammation-related depression: a prospective study of breast cancer survivors.

Authors:  Andrew W Manigault; Patricia A Ganz; Michael R Irwin; Steve W Cole; Kate R Kuhlman; Julienne E Bower
Journal:  Transl Psychiatry       Date:  2021-12-06       Impact factor: 6.222

Review 9.  Sick for science: experimental endotoxemia as a translational tool to develop and test new therapies for inflammation-associated depression.

Authors:  Julie Lasselin; Mats Lekander; Sven Benson; Manfred Schedlowski; Harald Engler
Journal:  Mol Psychiatry       Date:  2020-09-01       Impact factor: 15.992

10.  Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.

Authors:  Vincent Millischer; Matthias Heinzl; Anthi Faka; Michael Resl; Ada Trepci; Carmen Klammer; Margot Egger; Benjamin Dieplinger; Martin Clodi; Lilly Schwieler
Journal:  J Neuroinflammation       Date:  2021-07-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.